Temozolomide for advanced melanoma with a BAP1 gene change
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a chemotherapy drug called temozolomide for people with advanced melanoma (skin cancer) that has a specific genetic change called BAP1. The drug may help shrink tumors or slow the cancer's growth, especially for people who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced melanoma (stage III that cannot be removed by surgery or stage IV) that has spread, and it has a BAP1 gene change.
- You have already tried at least one type of immunotherapy (like PD-1 inhibitors) AND, if your cancer has a BRAF mutation, you have also tried targeted therapy (BRAF and MEK inhibitors).
- You have not had chemotherapy for your melanoma before.
- Your general health is reasonably good (able to care for yourself, though you may need some help).
- You have not had other cancers recently, except for certain skin cancers or a cancer cured more than 2 years ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
This trial tests a combination of three drugs (Fluzoparib, Camrelizumab, and Temozolomide) for people with advanced melanoma that has spread or cannot be removed by surgery. It is for those who have a specific genetic change (HR or SF3B1 mutation) and have not been treated with a PARP inhibitor before.
This study tests a combination of three drugs for people with advanced melanoma that has not responded to previous treatment. The goal is to see if this combination can help control the cancer.
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.